Tocofersolan
Names | |
---|---|
IUPAC name α-Hydro-ω-{[4-oxo-4-({(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-yl}oxy)butanoyl]oxy}poly(oxyethylene) | |
Other names Tocofersolan; Vitamin E PEG succinate; α-Tocopherol polyethylene glycol succinate (TPGS); Liqui-E | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEMBL |
|
ChemSpider |
|
DrugBank |
|
ECHA InfoCard | 100.123.651 |
EC Number |
|
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
Properties | |
Chemical formula | (C2H4O)nC33H54O5 |
Molar mass | Variable |
Pharmacology | |
A11HA08 (WHO) | |
License data |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references |
Clinical data | |
---|---|
Trade names | Vedrop |
Other names | Tocophersolan (USAN US) |
AHFS/Drugs.com | UK Drug Information |
Legal status | |
Legal status | |
Identifiers | |
DrugBank |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.123.651 |
Tocofersolan (INN) or tocophersolan, also referred to as TPGS (for tocopherol polyethylene glycol succinate), is a synthetic water-soluble version of vitamin E. Natural forms of vitamin E are fat soluble, but not water-soluble. Tocofersolan is polyethylene glycol derivative of α-tocopherol that enables water solubility.
Tocofersolan is used as a vitamin E supplement or to treat vitamin E deficiency in individuals who cannot absorb fats due to disease.[3] On 24 July 2009 the European Medicines Agency approved tocofersolan under the trade name Vedrop 50 mg/ml oral solution for the treatment of vitamin E deficiency due to digestive malabsorption in paediatric patients with congenital or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age (depending on the region).[4]
Tocofersolan is also used in cosmetics and pharmaceuticals as an antioxidant.[5]
References
- ^ "Vedrop 50 mg/ml oral solution - Summary of Product Characteristics (SmPC)". (emc). 19 June 2019. Retrieved 24 July 2020.
- ^ "Vedrop EPAR". European Medicines Agency (EMA). Retrieved 24 July 2020.
- ^ "Tocophersolan Oral". WebMD.
- ^ "Vedrop Summary of Product Characteristics" (PDF). European Medicines Agency.[permanent dead link]
- ^ Ash M, Ash I (2004). Handbook of Preservatives. Synapse Info Resources. p. 568. ISBN 1-890595-66-7.
- v
- t
- e
soluble
A | |
---|---|
D | |
E |
|
K |
|
soluble
B |
|
---|---|
C |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e